NCCN Collaborates with Pfizer to Explore Adoption of Biosimilars in Oncology

Shots: NCCN and Pfizer have issued an open RFP that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology The RFP supports approaches to improve the processes related to biosimilar adoption in oncology. Letters of Intent are welcome from academic or community centers, patient advocacy groups and …

NCCN Collaborates with Pfizer to Explore Adoption of Biosimilars in Oncology Read More »